Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29849717 | 0.78 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL18291307 | 0.75 | CHRNB2 (0.59) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL4839072 | 0.74 | CSNK1E (0.49) | CHRNB2CHRNA4PARP1CHRNB4CHRNA3 | |
| SCHEMBL13103767 | 0.74 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1108656 | 0.74 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL7690443 | 0.70 | CHRNB2 (0.64) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL5043519 | 0.70 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL22425334 | 0.70 | CHRNB2 (0.53) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL7690304 | 0.70 | CHRNB2 (0.64) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL26165435 | 0.70 | CHRNB2 (0.47) | CHRNB2CHRNA4PARP1CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2615089-B1 | Pyrazoloquinoline compounds | ASTELLAS PHARMA INC (JP) | 2016-04-27 | — | — | EP | disclosed |
| US-8822448-B2 | Pyrazoloquinoline compound | ASTELLAS PHARMA INC. (JP) | 2014-09-02 | — | — | US | disclosed |
| US-8822448-B2 | Pyrazoloquinoline compound | ASTELLAS PHARMA INC. (JP) | 2014-09-02 | — | — | US | disclosed |
| US-20130225553-A1 | PYRAZOLOQUINOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-08-29 | — | — | US | disclosed |
| US-20130225553-A1 | PYRAZOLOQUINOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225553-A1 | PYRAZOLOQUINOLINE COMPOUND | PDE9A, PDE5A, PDE2A | CHRNB2 3579/4885CHRNA4 2911/4885PARP1 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.